The gene that, when mutated, causes Fragile X syndrome.
Related Articles:
- Coming Full Circle – Kathy May Returns back to FRAXACo-Founder Kathy May returns after two decades to share her story. It’s about discovering new forms of treatments to enhance the mental, emotional and social growth of those affected by Fragile X. “And there will be a cure,” she said. “FRAXA is the reason for this hope. I have come full circle to FRAXA and feeling more hopeful than I have in many years.”
- Positive Results Reported in Phase II Fragile X Clinical Trial of PDE4D Inhibitor Zatolmilast from Tetra TherapeuticsToday, Tetra Therapeutics announces the first unequivocally positive phase 2 clinical trial in Fragile X syndrome, press release below. The results do not depend on carving out a subset of patients or post hoc analysis.
- Repurposing FDA-Approved Drugs to Treat Major Depressive Disorder in Fragile X SyndromeDid you know that depression is more common in those with autism and/or Fragile X? Even more disturbing is the discovery that current treatments for depression do not work in Fragile X mice. With this grant, the team will work to develop a rapid screening tool to identify FDA-approved drugs which can treat depression in people with Fragile X syndrome.
- Recruiting: Tetra Therapeutics Phase 3 Clinical Trial of Zatolmilast in Fragile X SyndromeTetra Therapeutics has launched large scale clinical trials of their phosphodiesterase (PDE) inhibitor for males ages 9-45 with Fragile X syndrome. FRAXA Research Foundation's basic and translational research pointed the way to phosphodiesterase inhibitors to treat Fragile X.
- Fragile X Syndrome TimelineDiscover the evolution of Fragile X research through the work of FRAXA Research Foundation, which is dedicated to finding effective treatments and ultimately a cure for Fragile X syndrome. This interactive timeline showcases milestones, breakthroughs, and key events that have shaped our evolving understanding of Fragile X syndrome.